我们提供澳大利亚代理人的服务，以确保合规性并协助您的产品进入澳大利亚市场。CMC Medical Devices PTY LTD 作为您的TGA代理人和法规顾问，为您提供支持，确保符合TGA的技术要求以及上市后的合规性。
总部不在澳大利亚的医疗器械和IVD制造商必须在该国命名一位澳大利亚或TGA代理人。
您的TGA代理人在器械注册过程和上市后合规性中起着至关重要的作用，因此选择独立且有资质的代理人非常重要。
CMC是全球医疗器械和IVD公司的专业代理人。
根据1989年《治疗用品法》和2002年《治疗用品(医疗器械)条例》的规定，代理人是作为您和TGA之间的联络人。代理人承担产品在澳大利亚市场的监管代表，并负责向TGA注册您的设备。
为了保持对你们的医疗器械和IVD注册的控制，我们建议你们指定一个“第三方”代理人，其在商业上不参与您产品的销售，仅作为您在澳大利亚的监管代表。
我们作为澳大利亚TGA代理人的职责
-
在商业化之前向TGA注册您的医疗器械和IVD。
-
作为你与TGA的主要联系人。
-
确保你的技术文件可以被TGA检查。
-
授权将我们的名称和地址放在您的设备的标签、包装、使用说明等上。
-
内部监管专家在您和TGA之间进行联络。
-
协助监督:与您和您的经销商合作，向TGA报告可报告的召回/不良事件。
-
保密文件的保护:赞助商只能向TGA展示。
-
在医疗器械召回的情况下，代表您在TGA咨询。
-
确保在线访问信息和标签符号、技术文件模板、质量体系程序(QSP或SOP)、医疗器械法规、监测指南、分类指南、市场召回/可报告的不良事件、协调标准等。
Frequently asked questions about TGA Registration
Manufacturers based outside the EU are legally obliged to appoint an Authorized Representative (EC REP) so that their products can legally circulate within the European Union market.
Regardless of whether a medical device requires the intervention of a Notified Body (in the case of Class I sterile/measuring/reusable, IIa, IIb and III) to obtain CE Marking, or whether the manufacturer can self-certify (Class I simple), those operating outside the EU must appoint an Authorized Representative so that their products can be placed on the European market.
The Authorized Representative plays a crucial role in ensuring device compliance, acting as the point of contact within the Union. The Authorized Representative’s minimum responsibilities include:
● Verifying that the technical documentation and other essential documents have been prepared and that the manufacturer has fulfilled its registration obligations.
● Providing the competent authority with all information and documentation necessary to demonstrate the conformity of a device.
● Transmit to the manufacturer any request from the competent authority to obtain samples of the device.
● Collaborate with the competent authorities in any preventive or corrective actions aimed at eliminating or mitigating risks that devices may present.
● Immediately inform the manufacturer of complaints and reports from healthcare professionals, patients and users about possible incidents related to a device for which they have been designated.
The European Authorized Representative (EC-REP or EAR) shares responsibility in case of defective products and is obliged to terminate the contract with the manufacturer if the manufacturer acts inconsistently with its obligations. Therefore, the EAR is responsible for defective products when the manufacturer has not fulfilled its obligations under the Medical Device Regulation (MDR).
Yes. Any manufacturer that is established outside the European Union is required to appoint an Authorized Representative (EC REP) based in the EU.
This requirement is essential for placing medical devices or IVDs on the market in accordance with Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR).
Without a designated EC REP, it is not legally possible to access the European market.
Not always. In some cases, an importer or distributor can be designated as the Authorized Representative, but this must be done formally and in full compliance with legal requirements.
However, this practice may lead to conflicts of interest.
Therefore, it is recommended to choose an independent EC REP with expertise in regulatory compliance.
Yes. The name and address of the Authorized Representative must appear on the product labeling, the outer packaging, or the Instructions for Use (IFU).
In addition, the official EC REP symbol, as specified in ISO 15223-1, must be included.
This information must be clear, visible, and legible to meet the requirements of the MDR and IVDR.
Yes. It is possible to change your Authorized Representative at any time.
The current and new EC REPs must coordinate the transfer of responsibilities to maintain regulatory compliance.
The manufacturer must also update the labeling, technical documentation, and EUDAMED records, if applicable.
For medical devices and in-vitro diagnostic devices, EU Regulations (MDR and IVDR) mandate that non-EU manufacturers appoint an authorized representative based in the EU. This representative is crucial for ensuring compliance and acts as a primary contact point within the EU.
Since 2014, CMC Medical Devices has been dedicated to providing representation and consultancy services to manufacturers seeking entry into the EU market. Our headquarters, located in Spain, places us strategically to work closely with EU institutions. We are actively involved in European Commission Working Groups and Horizon Europe, the EU’s research and innovation program, shaping the compliance landscape over the years.
CMC Medical Devices is also a member of the European Association of Authorised Representatives (EAAR) and a founding member of the European Responsible Person Association (ERPA), both organizations committed to maintaining high standards of service and professionalism.
We highly recommend choosing a professional representative for your company within the EU. CMC Medical Devices offers:
● A team of experts to guide you through the compliance process
● Confidential handling of all shared information
● No conflict of interest, as we do not engage in manufacturing or selling products
● Up-to-date information on regulatory changes
Since our establishment, CMC Medical Devices has grown significantly and is a reference company in Europe for regulatory compliance. Our experts are well-equipped to help you navigate the EU, UK, and Swiss markets.
Why appoint CMC Medical Devices as your TGA Sponsor?
Fast response
We promptly and efficiently address any inquiries from authorities or regulatory bodies in the countries where we operate.
Efficient communication
Our team provides fast and clear responses to any questions or concerns, minimizing delays and ensuring a smooth approval process.
Immediate support
We handle inquiries and requests from both manufacturers and regulatory bodies with speed and precision.
Quick resolution
Any compliance questions or documentation needs are addressed promptly, ensuring your product moves through the regulatory process as quickly and smoothly as possible.
